National mass drug administration costs for lymphatic filariasis elimination.
Identifieur interne : 003479 ( PubMed/Curation ); précédent : 003478; suivant : 003480National mass drug administration costs for lymphatic filariasis elimination.
Auteurs : Ann S. Goldman [États-Unis] ; Victoria H. Guisinger ; Moses Aikins ; Maria Lourdes E. Amarillo ; Vicente Y. Belizario ; Bertha Garshong ; John Gyapong ; Conrad Kabali ; Hussein A. Kamal ; Sanjat Kanjilal ; Dominique Kyelem ; Jefrey Lizardo ; Mwele Malecela ; Godfrey Mubyazi ; P Abdoulaye Nitièma ; Reda M R. Ramzy ; Thomas G. Streit ; Aaron Wallace ; Molly A. Brady ; Richard Rheingans ; Eric A. Ottesen ; Anne C. HaddixSource :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2007.
Descripteurs français
- KwdFr :
- Albendazole (usage thérapeutique), Albendazole (économie), Antihelminthiques (usage thérapeutique), Antihelminthiques (économie), Burkina (épidémiologie), Coûts et analyse des coûts, Diéthylcarbamazine (usage thérapeutique), Diéthylcarbamazine (économie), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Ghana (épidémiologie), Haïti (épidémiologie), Humains, Philippines (épidémiologie), République dominicaine (épidémiologie), Tanzanie (épidémiologie), Traitement médicamenteux (), Traitement médicamenteux (économie), Égypte (épidémiologie), Éléphantiasis (), Éléphantiasis (traitement médicamenteux), Équipe soignante.
- MESH :
- traitement médicamenteux : Filariose lymphatique, Éléphantiasis.
- usage thérapeutique : Albendazole, Antihelminthiques, Diéthylcarbamazine.
- économie : Albendazole, Antihelminthiques, Diéthylcarbamazine, Traitement médicamenteux.
- épidémiologie : Burkina, Ghana, Haïti, Philippines, République dominicaine, Tanzanie, Égypte.
- Coûts et analyse des coûts, Filariose lymphatique, Humains, Traitement médicamenteux, Éléphantiasis, Équipe soignante.
- Wicri :
- geographic : Burkina Faso, République dominicaine, Égypte, Ghana, Haïti, Philippines.
English descriptors
- KwdEn :
- Albendazole (economics), Albendazole (therapeutic use), Anthelmintics (economics), Anthelmintics (therapeutic use), Burkina Faso (epidemiology), Costs and Cost Analysis, Diethylcarbamazine (economics), Diethylcarbamazine (therapeutic use), Dominican Republic (epidemiology), Drug Therapy (economics), Drug Therapy (methods), Egypt (epidemiology), Elephantiasis (drug therapy), Elephantiasis (prevention & control), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (prevention & control), Ghana (epidemiology), Haiti (epidemiology), Humans, Patient Care Team, Philippines (epidemiology), Tanzania (epidemiology).
- MESH :
- chemical , economics : Albendazole, Anthelmintics, Diethylcarbamazine.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine.
- geographic , epidemiology : Burkina Faso, Dominican Republic, Egypt, Ghana, Haiti, Philippines, Tanzania.
- drug therapy : Elephantiasis, Elephantiasis, Filarial.
- economics : Drug Therapy.
- methods : Drug Therapy.
- prevention & control : Elephantiasis, Elephantiasis, Filarial.
- Costs and Cost Analysis, Humans, Patient Care Team.
Abstract
Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk.
DOI: 10.1371/journal.pntd.0000067
PubMed: 17989784
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003479
Links to Exploration step
pubmed:17989784Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">National mass drug administration costs for lymphatic filariasis elimination.</title><author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S" last="Goldman">Ann S. Goldman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC, United States of America. sphasg@gwumc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC</wicri:regionArea></affiliation></author><author><name sortKey="Guisinger, Victoria H" sort="Guisinger, Victoria H" uniqKey="Guisinger V" first="Victoria H" last="Guisinger">Victoria H. Guisinger</name></author><author><name sortKey="Aikins, Moses" sort="Aikins, Moses" uniqKey="Aikins M" first="Moses" last="Aikins">Moses Aikins</name></author><author><name sortKey="Amarillo, Maria Lourdes E" sort="Amarillo, Maria Lourdes E" uniqKey="Amarillo M" first="Maria Lourdes E" last="Amarillo">Maria Lourdes E. Amarillo</name></author><author><name sortKey="Belizario, Vicente Y" sort="Belizario, Vicente Y" uniqKey="Belizario V" first="Vicente Y" last="Belizario">Vicente Y. Belizario</name></author><author><name sortKey="Garshong, Bertha" sort="Garshong, Bertha" uniqKey="Garshong B" first="Bertha" last="Garshong">Bertha Garshong</name></author><author><name sortKey="Gyapong, John" sort="Gyapong, John" uniqKey="Gyapong J" first="John" last="Gyapong">John Gyapong</name></author><author><name sortKey="Kabali, Conrad" sort="Kabali, Conrad" uniqKey="Kabali C" first="Conrad" last="Kabali">Conrad Kabali</name></author><author><name sortKey="Kamal, Hussein A" sort="Kamal, Hussein A" uniqKey="Kamal H" first="Hussein A" last="Kamal">Hussein A. Kamal</name></author><author><name sortKey="Kanjilal, Sanjat" sort="Kanjilal, Sanjat" uniqKey="Kanjilal S" first="Sanjat" last="Kanjilal">Sanjat Kanjilal</name></author><author><name sortKey="Kyelem, Dominique" sort="Kyelem, Dominique" uniqKey="Kyelem D" first="Dominique" last="Kyelem">Dominique Kyelem</name></author><author><name sortKey="Lizardo, Jefrey" sort="Lizardo, Jefrey" uniqKey="Lizardo J" first="Jefrey" last="Lizardo">Jefrey Lizardo</name></author><author><name sortKey="Malecela, Mwele" sort="Malecela, Mwele" uniqKey="Malecela M" first="Mwele" last="Malecela">Mwele Malecela</name></author><author><name sortKey="Mubyazi, Godfrey" sort="Mubyazi, Godfrey" uniqKey="Mubyazi G" first="Godfrey" last="Mubyazi">Godfrey Mubyazi</name></author><author><name sortKey="Nitiema, P Abdoulaye" sort="Nitiema, P Abdoulaye" uniqKey="Nitiema P" first="P Abdoulaye" last="Nitièma">P Abdoulaye Nitièma</name></author><author><name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M R" last="Ramzy">Reda M R. Ramzy</name></author><author><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></author><author><name sortKey="Wallace, Aaron" sort="Wallace, Aaron" uniqKey="Wallace A" first="Aaron" last="Wallace">Aaron Wallace</name></author><author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name></author><author><name sortKey="Rheingans, Richard" sort="Rheingans, Richard" uniqKey="Rheingans R" first="Richard" last="Rheingans">Richard Rheingans</name></author><author><name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A" last="Ottesen">Eric A. Ottesen</name></author><author><name sortKey="Haddix, Anne C" sort="Haddix, Anne C" uniqKey="Haddix A" first="Anne C" last="Haddix">Anne C. Haddix</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17989784</idno><idno type="pmid">17989784</idno><idno type="doi">10.1371/journal.pntd.0000067</idno><idno type="wicri:Area/PubMed/Corpus">003479</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003479</idno><idno type="wicri:Area/PubMed/Curation">003479</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003479</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">National mass drug administration costs for lymphatic filariasis elimination.</title><author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S" last="Goldman">Ann S. Goldman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC, United States of America. sphasg@gwumc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC</wicri:regionArea></affiliation></author><author><name sortKey="Guisinger, Victoria H" sort="Guisinger, Victoria H" uniqKey="Guisinger V" first="Victoria H" last="Guisinger">Victoria H. Guisinger</name></author><author><name sortKey="Aikins, Moses" sort="Aikins, Moses" uniqKey="Aikins M" first="Moses" last="Aikins">Moses Aikins</name></author><author><name sortKey="Amarillo, Maria Lourdes E" sort="Amarillo, Maria Lourdes E" uniqKey="Amarillo M" first="Maria Lourdes E" last="Amarillo">Maria Lourdes E. Amarillo</name></author><author><name sortKey="Belizario, Vicente Y" sort="Belizario, Vicente Y" uniqKey="Belizario V" first="Vicente Y" last="Belizario">Vicente Y. Belizario</name></author><author><name sortKey="Garshong, Bertha" sort="Garshong, Bertha" uniqKey="Garshong B" first="Bertha" last="Garshong">Bertha Garshong</name></author><author><name sortKey="Gyapong, John" sort="Gyapong, John" uniqKey="Gyapong J" first="John" last="Gyapong">John Gyapong</name></author><author><name sortKey="Kabali, Conrad" sort="Kabali, Conrad" uniqKey="Kabali C" first="Conrad" last="Kabali">Conrad Kabali</name></author><author><name sortKey="Kamal, Hussein A" sort="Kamal, Hussein A" uniqKey="Kamal H" first="Hussein A" last="Kamal">Hussein A. Kamal</name></author><author><name sortKey="Kanjilal, Sanjat" sort="Kanjilal, Sanjat" uniqKey="Kanjilal S" first="Sanjat" last="Kanjilal">Sanjat Kanjilal</name></author><author><name sortKey="Kyelem, Dominique" sort="Kyelem, Dominique" uniqKey="Kyelem D" first="Dominique" last="Kyelem">Dominique Kyelem</name></author><author><name sortKey="Lizardo, Jefrey" sort="Lizardo, Jefrey" uniqKey="Lizardo J" first="Jefrey" last="Lizardo">Jefrey Lizardo</name></author><author><name sortKey="Malecela, Mwele" sort="Malecela, Mwele" uniqKey="Malecela M" first="Mwele" last="Malecela">Mwele Malecela</name></author><author><name sortKey="Mubyazi, Godfrey" sort="Mubyazi, Godfrey" uniqKey="Mubyazi G" first="Godfrey" last="Mubyazi">Godfrey Mubyazi</name></author><author><name sortKey="Nitiema, P Abdoulaye" sort="Nitiema, P Abdoulaye" uniqKey="Nitiema P" first="P Abdoulaye" last="Nitièma">P Abdoulaye Nitièma</name></author><author><name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M R" last="Ramzy">Reda M R. Ramzy</name></author><author><name sortKey="Streit, Thomas G" sort="Streit, Thomas G" uniqKey="Streit T" first="Thomas G" last="Streit">Thomas G. Streit</name></author><author><name sortKey="Wallace, Aaron" sort="Wallace, Aaron" uniqKey="Wallace A" first="Aaron" last="Wallace">Aaron Wallace</name></author><author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name></author><author><name sortKey="Rheingans, Richard" sort="Rheingans, Richard" uniqKey="Rheingans R" first="Richard" last="Rheingans">Richard Rheingans</name></author><author><name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A" last="Ottesen">Eric A. Ottesen</name></author><author><name sortKey="Haddix, Anne C" sort="Haddix, Anne C" uniqKey="Haddix A" first="Anne C" last="Haddix">Anne C. Haddix</name></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (economics)</term><term>Albendazole (therapeutic use)</term><term>Anthelmintics (economics)</term><term>Anthelmintics (therapeutic use)</term><term>Burkina Faso (epidemiology)</term><term>Costs and Cost Analysis</term><term>Diethylcarbamazine (economics)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Dominican Republic (epidemiology)</term><term>Drug Therapy (economics)</term><term>Drug Therapy (methods)</term><term>Egypt (epidemiology)</term><term>Elephantiasis (drug therapy)</term><term>Elephantiasis (prevention & control)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Ghana (epidemiology)</term><term>Haiti (epidemiology)</term><term>Humans</term><term>Patient Care Team</term><term>Philippines (epidemiology)</term><term>Tanzania (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (usage thérapeutique)</term><term>Albendazole (économie)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Antihelminthiques (économie)</term><term>Burkina (épidémiologie)</term><term>Coûts et analyse des coûts</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Diéthylcarbamazine (économie)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Ghana (épidémiologie)</term><term>Haïti (épidémiologie)</term><term>Humains</term><term>Philippines (épidémiologie)</term><term>République dominicaine (épidémiologie)</term><term>Tanzanie (épidémiologie)</term><term>Traitement médicamenteux ()</term><term>Traitement médicamenteux (économie)</term><term>Égypte (épidémiologie)</term><term>Éléphantiasis ()</term><term>Éléphantiasis (traitement médicamenteux)</term><term>Équipe soignante</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Burkina Faso</term><term>Dominican Republic</term><term>Egypt</term><term>Ghana</term><term>Haiti</term><term>Philippines</term><term>Tanzania</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Éléphantiasis</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Traitement médicamenteux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Burkina</term><term>Ghana</term><term>Haïti</term><term>Philippines</term><term>République dominicaine</term><term>Tanzanie</term><term>Égypte</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Costs and Cost Analysis</term><term>Humans</term><term>Patient Care Team</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coûts et analyse des coûts</term><term>Filariose lymphatique</term><term>Humains</term><term>Traitement médicamenteux</term><term>Éléphantiasis</term><term>Équipe soignante</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Burkina Faso</term><term>République dominicaine</term><term>Égypte</term><term>Ghana</term><term>Haïti</term><term>Philippines</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17989784</PMID><DateCreated><Year>2007</Year><Month>11</Month><Day>08</Day></DateCreated><DateCompleted><Year>2010</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>National mass drug administration costs for lymphatic filariasis elimination.</ArticleTitle><Pagination><MedlinePgn>e67</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">To obtain annual costs to carry out the MDA strategy, researchers from seven countries developed and followed a common cost analysis protocol designed to estimate 1) the total annual cost of the LF program, 2) the average cost per person treated, and 3) the relative contributions of the endemic countries and the external partners. Costs per person treated ranged from $0.06 to $2.23. Principal reasons for the variation were 1) the age (newness) of the MDA program, 2) the use of volunteers, and 3) the size of the population treated. Substantial contributions by governments were documented - generally 60%-90% of program operation costs, excluding costs of donated medications.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">MDA for LF elimination is comparatively inexpensive in relation to most other public health programs. Governments and communities make the predominant financial contributions to actual MDA implementation, not counting the cost of the drugs themselves. The results highlight the impact of the use of volunteers on program costs and provide specific cost data for 7 different countries that can be used as a basis both for modifying current programs and for developing new ones.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Ann S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC, United States of America. sphasg@gwumc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guisinger</LastName><ForeName>Victoria H</ForeName><Initials>VH</Initials></Author><Author ValidYN="Y"><LastName>Aikins</LastName><ForeName>Moses</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Amarillo</LastName><ForeName>Maria Lourdes E</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Belizario</LastName><ForeName>Vicente Y</ForeName><Initials>VY</Initials></Author><Author ValidYN="Y"><LastName>Garshong</LastName><ForeName>Bertha</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gyapong</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kabali</LastName><ForeName>Conrad</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kamal</LastName><ForeName>Hussein A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Kanjilal</LastName><ForeName>Sanjat</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kyelem</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lizardo</LastName><ForeName>Jefrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Malecela</LastName><ForeName>Mwele</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mubyazi</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nitièma</LastName><ForeName>P Abdoulaye</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Ramzy</LastName><ForeName>Reda M R</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Streit</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Molly A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Rheingans</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ottesen</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Haddix</LastName><ForeName>Anne C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2004 Aug;9(8):843-5</RefSource><PMID Version="1">15303987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 1998 Jan-Feb;92(1):94-7</RefSource><PMID Version="1">9692166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 1999 Jan;4(1):19-25</RefSource><PMID Version="1">10203169</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2003 Jul 21;2(1):12</RefSource><PMID Version="1">12914666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Apr 8;367(9517):1193-208</RefSource><PMID Version="1">16616562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 Mar 19-25;365(9464):1029-30</RefSource><PMID Version="1">15781095</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 1996 Feb;90(1):39-48</RefSource><PMID Version="1">8729626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>MMWR Recomm Rep. 1993 Dec 31;42(RR-16):1-38</RefSource><PMID Version="1">8145708</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Health Policy. 2002 Oct;62(1):31-51</RefSource><PMID Version="1">12151133</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2003 Nov;69(5 Suppl):24-8</RefSource><PMID Version="1">14692677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2005 Aug 02;4:7</RefSource><PMID Version="1">16076397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S77-90</RefSource><PMID Version="1">12625921</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2000 Sep;5(9):591-4</RefSource><PMID Version="1">11044272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 2000 Jun;16(6):251-3</RefSource><PMID Version="1">10827432</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2006 Jun 2;81(22):221-32</RefSource><PMID Version="1">16749186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2006 Jul;22(7):285-91</RefSource><PMID Version="1">16730230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2005 Nov;73(5):888-94</RefSource><PMID Version="1">16282299</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002050" MajorTopicYN="N" Type="Geographic">Burkina Faso</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004293" MajorTopicYN="N" Type="Geographic">Dominican Republic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004534" MajorTopicYN="N" Type="Geographic">Egypt</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004604" MajorTopicYN="N">Elephantiasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006205" MajorTopicYN="N" Type="Geographic">Haiti</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010679" MajorTopicYN="N" Type="Geographic">Philippines</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013636" MajorTopicYN="N" Type="Geographic">Tanzania</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC2041814</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17989784</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0000067</ArticleId><ArticleId IdType="pmc">PMC2041814</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003479 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003479 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17989784
|texte= National mass drug administration costs for lymphatic filariasis elimination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17989784" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |